Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Kyverna Therapeutics, Inc.’s reported figures.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
FAQ
- What is Kyverna Therapeutics, Inc.'s EBIT?
- Kyverna Therapeutics, Inc. (KYTX) reported EBIT of -$41.37M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s EBIT changed year-over-year?
- Kyverna Therapeutics, Inc.'s EBIT increased by 12.7% year-over-year, from -$47.41M to -$41.37M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s EBIT?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s EBIT has grown at a 65.0% compound annual growth rate (CAGR), from -$62.41M to -$169.83M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Kyverna Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude